MA has restated its disappointment at the health department's failure to consult on the attempt to defer submissions from consideration at the March PBAC meeting following the release of advice that shows officials advised Mark Butler it was "critical" to "mitigate" the reputational risks to the government.
'We are very unhappy that we were not consulted as it is an expectation'
December 3, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News -
Pharmac marks 12-month anniversary of funding boost
July 25, 2025 - - Latest News -
AccessCR announces finalists in Consumer Partnerships in Research Awards
July 24, 2025 - - Latest News -
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close
July 24, 2025 - - Australian Biotech -
Australia on the list of countries to be targeted over pharmaceutical pricing
July 24, 2025 - - Latest News -
Latest trade agreements reveal US focus on resolving longstanding issues
July 24, 2025 - - Latest News -
Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology
July 23, 2025 - - Australian Biotech